Quotient Sciences Header

Quotient Sciences Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Orion Biotechnology","sponsor":"National Research Council Industrial Research Assistance Program","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Orion Biotechnology Receives Funding to Test OB-002 for Treatment of COVID-19","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Orion Biotechnology"},{"company":"Bausch Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bausch Health's LUMIFY\u00ae and BESIVANCE\u00ae Eye Drops Preserved With Benzalkonium Chloride Completly Inactivats SARS-CoV-2","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"November 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Bausch Health"},{"company":"adMare BioInnovations","sponsor":"AazeinTX","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AdMare and AazeinTx Inc. Sign Global Exclusive Agreement for Promising Acute Asthma Treatment (NEO6860)","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"adMare BioInnovations"}]

adMare BioInnovations

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

AdMare and AazeinTx Inc. Sign Global Exclusive Agreement for Promising Acute Asthma Treatment (NEO6860)

Details:

AazeinTx has acquired all rights to NEO6860, a clinical-stage TRPV1 antagonist in adMare’s technology portfolio. With a team at the University of Calgary led by Dr. Richard Wilson AazeinTx proposes to bring a pill-based form of NEO6860.

Lead Product(s): NEO6860

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: NEO6860

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: AazeinTX

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement May 17, 2021

ASK
US

Upload
your Pipeline Activity

Bausch Health

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Bausch Health's LUMIFY® and BESIVANCE® Eye Drops Preserved With Benzalkonium Chloride Completly Inactivats SARS-CoV-2

Details:

Results of new investigational in vitro data shows that two benzalkonium chloride preserved eye drops, LUMIFY® redness reliever eye drops and BESIVANCE® 0.6%, indicated complete inactivation of Severe Acute Respiratory Syndrome-related Coronavirus 2 (SARS-CoV-2 or COVID-19).

Lead Product(s): Brimonidine Tartrate

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Lumify

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 16, 2020

ASK
US

Upload
your Pipeline Activity

Orion Biotechnology

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Orion Biotechnology Receives Funding to Test OB-002 for Treatment of COVID-19

Details:

Funding from the National Research Council Industrial Research Assistance Program will support the development of Orion’s lead compound, OB-002, a promising treatment for SARS-CoV-2 infection associated acute respiratory distress syndrome (ARDS).

Lead Product(s): OB-002

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: OB-002

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: National Research Council Industrial Research Assistance Program

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Funding July 30, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY